Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases.

Shiro Kitamoto, Kensuke Egashira

    Research output: Contribution to journalReview articlepeer-review

    30 Citations (Scopus)


    Recent studies have revealed that increased expression of monocyte chemoattractant protein (MCP)-1 plays a central role in the pathogenesis of cardiovascular diseases. 7ND is the amino-terminal deletion mutant of human MCP-1 and works as a dominant negative inhibitor of MCP-1. We devised a new strategy of anti-MCP-1 gene therapy by transfecting the 7ND gene into skeletal muscles. 7ND gene transfection suppressed arteriosclerotic changes induced by chronic inhibition of nitric oxide synthesis in rats and inhibited the development, progression and destabilization of atherosclerosis in apolipoprotein E knockout mice. This strategy also reduced restenosis after balloon injury in rats, rabbits and monkeys, and reduced neointimal formation after stent implantation in rabbits and monkeys. This new strategy can be a useful and feasible gene therapy against MCP-1 related cardiovascular diseases.

    Original languageEnglish
    Pages (from-to)393-400
    Number of pages8
    JournalExpert review of cardiovascular therapy
    Issue number3
    Publication statusPublished - Sept 2003

    All Science Journal Classification (ASJC) codes

    • Internal Medicine
    • Cardiology and Cardiovascular Medicine


    Dive into the research topics of 'Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases.'. Together they form a unique fingerprint.

    Cite this